Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts

A proof-of-concept randomized clinical trial

Rubens Moreno De Freitas, Cristiano Susin, Rubens Spin-Neto, Claudio Marcantonio, Ulf M E Wikesjö, Luís Antônio Violin Dias Pereira, Elcio Marcantonio

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aim To compare the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge carrier (ACS) with autogenous bone graft for augmentation of the edentulous atrophic anterior maxilla. Methods Twenty-four subjects were enrolled in a randomized, controlled, parallel-group, open-label clinical trial. Subjects either received rhBMP-2/ACS (1.5 mg/ml) or particulated autogenous bone harvested from the mandibular retromolar region. A titanium-mesh was used to provide space and wound stability. A guide was used to standardize clinical recordings using an analogue caliper. Alveolar ridge width was also assessed using cone-beam computed tomography. Results rhBMP-2/ACS yielded significantly greater radiographic horizontal bone gain compared with autogenous bone graft at immediate subcrestal levels (1.5 ± 0.7 versus 0.5 ± 0.9 mm; p = 0.01); non-significant differences were observed at mid- (2.9 ± 0.8 versus 2.9 ± 0.9 mm; p = 0.98) and apical (1.7 ± 0.9 versus 1.8 ± 1.1 mm; p = 0.85) crestal levels. No significant differences in clinical horizontal bone gain were observed at 6 months between rhBMP-2/ACS and autogenous bone graft (3.2 ± 0.9 mm versus 3.7 ± 1.4 mm; p = 0.31). Sixty-two implants were placed after 6 month of healing with no significant differences between groups for number of implants, implant size, primary stability and survival. Conclusions rhBMP-2/ACS appears a realistic alternative for augmentation of the edentulous atrophic anterior maxilla.

Original languageEnglish (US)
Pages (from-to)968-975
Number of pages8
JournalJournal of Clinical Periodontology
Volume40
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Maxilla
Porifera
Collagen
Randomized Controlled Trials
Transplants
Bone and Bones
Alveolar Process
Cone-Beam Computed Tomography
Titanium
recombinant human bone morphogenetic protein-2
Clinical Trials
Wounds and Injuries

Keywords

  • alveolar ridge augmentation
  • autogenous bone graft
  • randomized-controlled trial
  • recombinant human bone morphogenetic protein
  • rhBMP-2

ASJC Scopus subject areas

  • Periodontics

Cite this

De Freitas, R. M., Susin, C., Spin-Neto, R., Marcantonio, C., Wikesjö, U. M. E., Pereira, L. A. V. D., & Marcantonio, E. (2013). Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts: A proof-of-concept randomized clinical trial. Journal of Clinical Periodontology, 40(10), 968-975. https://doi.org/10.1111/jcpe.12148

Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts : A proof-of-concept randomized clinical trial. / De Freitas, Rubens Moreno; Susin, Cristiano; Spin-Neto, Rubens; Marcantonio, Claudio; Wikesjö, Ulf M E; Pereira, Luís Antônio Violin Dias; Marcantonio, Elcio.

In: Journal of Clinical Periodontology, Vol. 40, No. 10, 01.10.2013, p. 968-975.

Research output: Contribution to journalArticle

De Freitas, Rubens Moreno ; Susin, Cristiano ; Spin-Neto, Rubens ; Marcantonio, Claudio ; Wikesjö, Ulf M E ; Pereira, Luís Antônio Violin Dias ; Marcantonio, Elcio. / Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts : A proof-of-concept randomized clinical trial. In: Journal of Clinical Periodontology. 2013 ; Vol. 40, No. 10. pp. 968-975.
@article{c3b6372b77a641b0a3560ce6133272c0,
title = "Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts: A proof-of-concept randomized clinical trial",
abstract = "Aim To compare the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge carrier (ACS) with autogenous bone graft for augmentation of the edentulous atrophic anterior maxilla. Methods Twenty-four subjects were enrolled in a randomized, controlled, parallel-group, open-label clinical trial. Subjects either received rhBMP-2/ACS (1.5 mg/ml) or particulated autogenous bone harvested from the mandibular retromolar region. A titanium-mesh was used to provide space and wound stability. A guide was used to standardize clinical recordings using an analogue caliper. Alveolar ridge width was also assessed using cone-beam computed tomography. Results rhBMP-2/ACS yielded significantly greater radiographic horizontal bone gain compared with autogenous bone graft at immediate subcrestal levels (1.5 ± 0.7 versus 0.5 ± 0.9 mm; p = 0.01); non-significant differences were observed at mid- (2.9 ± 0.8 versus 2.9 ± 0.9 mm; p = 0.98) and apical (1.7 ± 0.9 versus 1.8 ± 1.1 mm; p = 0.85) crestal levels. No significant differences in clinical horizontal bone gain were observed at 6 months between rhBMP-2/ACS and autogenous bone graft (3.2 ± 0.9 mm versus 3.7 ± 1.4 mm; p = 0.31). Sixty-two implants were placed after 6 month of healing with no significant differences between groups for number of implants, implant size, primary stability and survival. Conclusions rhBMP-2/ACS appears a realistic alternative for augmentation of the edentulous atrophic anterior maxilla.",
keywords = "alveolar ridge augmentation, autogenous bone graft, randomized-controlled trial, recombinant human bone morphogenetic protein, rhBMP-2",
author = "{De Freitas}, {Rubens Moreno} and Cristiano Susin and Rubens Spin-Neto and Claudio Marcantonio and Wikesj{\"o}, {Ulf M E} and Pereira, {Lu{\'i}s Ant{\^o}nio Violin Dias} and Elcio Marcantonio",
year = "2013",
month = "10",
day = "1",
doi = "10.1111/jcpe.12148",
language = "English (US)",
volume = "40",
pages = "968--975",
journal = "Journal of Clinical Periodontology",
issn = "0303-6979",
publisher = "Blackwell Munksgaard",
number = "10",

}

TY - JOUR

T1 - Horizontal ridge augmentation of the atrophic anterior maxilla using rhBMP-2/ACS or autogenous bone grafts

T2 - A proof-of-concept randomized clinical trial

AU - De Freitas, Rubens Moreno

AU - Susin, Cristiano

AU - Spin-Neto, Rubens

AU - Marcantonio, Claudio

AU - Wikesjö, Ulf M E

AU - Pereira, Luís Antônio Violin Dias

AU - Marcantonio, Elcio

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Aim To compare the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge carrier (ACS) with autogenous bone graft for augmentation of the edentulous atrophic anterior maxilla. Methods Twenty-four subjects were enrolled in a randomized, controlled, parallel-group, open-label clinical trial. Subjects either received rhBMP-2/ACS (1.5 mg/ml) or particulated autogenous bone harvested from the mandibular retromolar region. A titanium-mesh was used to provide space and wound stability. A guide was used to standardize clinical recordings using an analogue caliper. Alveolar ridge width was also assessed using cone-beam computed tomography. Results rhBMP-2/ACS yielded significantly greater radiographic horizontal bone gain compared with autogenous bone graft at immediate subcrestal levels (1.5 ± 0.7 versus 0.5 ± 0.9 mm; p = 0.01); non-significant differences were observed at mid- (2.9 ± 0.8 versus 2.9 ± 0.9 mm; p = 0.98) and apical (1.7 ± 0.9 versus 1.8 ± 1.1 mm; p = 0.85) crestal levels. No significant differences in clinical horizontal bone gain were observed at 6 months between rhBMP-2/ACS and autogenous bone graft (3.2 ± 0.9 mm versus 3.7 ± 1.4 mm; p = 0.31). Sixty-two implants were placed after 6 month of healing with no significant differences between groups for number of implants, implant size, primary stability and survival. Conclusions rhBMP-2/ACS appears a realistic alternative for augmentation of the edentulous atrophic anterior maxilla.

AB - Aim To compare the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge carrier (ACS) with autogenous bone graft for augmentation of the edentulous atrophic anterior maxilla. Methods Twenty-four subjects were enrolled in a randomized, controlled, parallel-group, open-label clinical trial. Subjects either received rhBMP-2/ACS (1.5 mg/ml) or particulated autogenous bone harvested from the mandibular retromolar region. A titanium-mesh was used to provide space and wound stability. A guide was used to standardize clinical recordings using an analogue caliper. Alveolar ridge width was also assessed using cone-beam computed tomography. Results rhBMP-2/ACS yielded significantly greater radiographic horizontal bone gain compared with autogenous bone graft at immediate subcrestal levels (1.5 ± 0.7 versus 0.5 ± 0.9 mm; p = 0.01); non-significant differences were observed at mid- (2.9 ± 0.8 versus 2.9 ± 0.9 mm; p = 0.98) and apical (1.7 ± 0.9 versus 1.8 ± 1.1 mm; p = 0.85) crestal levels. No significant differences in clinical horizontal bone gain were observed at 6 months between rhBMP-2/ACS and autogenous bone graft (3.2 ± 0.9 mm versus 3.7 ± 1.4 mm; p = 0.31). Sixty-two implants were placed after 6 month of healing with no significant differences between groups for number of implants, implant size, primary stability and survival. Conclusions rhBMP-2/ACS appears a realistic alternative for augmentation of the edentulous atrophic anterior maxilla.

KW - alveolar ridge augmentation

KW - autogenous bone graft

KW - randomized-controlled trial

KW - recombinant human bone morphogenetic protein

KW - rhBMP-2

UR - http://www.scopus.com/inward/record.url?scp=84883509362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883509362&partnerID=8YFLogxK

U2 - 10.1111/jcpe.12148

DO - 10.1111/jcpe.12148

M3 - Article

VL - 40

SP - 968

EP - 975

JO - Journal of Clinical Periodontology

JF - Journal of Clinical Periodontology

SN - 0303-6979

IS - 10

ER -